Ann Lab Med.  2023 Jul;43(4):386-388. 10.3343/alm.2023.43.4.386.

Emergence of BCR-ABL1 (p190) in Acute Myeloid Leukemia Post-Gilteritinib Therapy

• Kim H
• Kim Is
• Kim H

• KMID: 2551957
• DOI: http://doi.org/10.3343/alm.2023.43.4.386

Figure

• 

  Fig. 1 Laboratory findings at the time of evaluation and therapy. Chromosomal testing and BME findings are indicated by red arrows. Dates are presented in the YY/MM/DD format. *FLT3-ITD AR was calculated as the ratio of the area under the curve of mutation to wild-type alleles by fragment analysis. Abbreviations: FLT3-ITD, FMS-like tyrosine kinase-3 internal tandem duplication; AR, allelic ratio; BM, bone marrow; BME, bone marrow examination; MTZ/AraC, mitoxantrone and cytarabine; AlloSCT, allogenic stem cell transplant.

Reference

1. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. 2016; Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 374:2209–21. DOI: 10.1056/NEJMoa1516192. PMID: 27276561. PMCID: PMC4979995.

2. Daver N, Schlenk RF, Russell NH, Levis MJ. 2019; Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 33:299–312. DOI: 10.1038/s41375-018-0357-9. PMID: 30651634. PMCID: PMC6365380.

3. Pulte ED, Norsworthy KJ, Wang Y, Xu Q, Qosa H, Gudi R, et al. 2021; FDA approval summary: gilteritinib for relapsed or refractory acute myeloid leukemia with a FLT3 mutation. Clin Cancer Res. 27:3515–21. DOI: 10.1158/1078-0432.CCR-20-4271. PMID: 33632926. PMCID: PMC8506653.

4. McMahon CM, Ferng T, Canaani J, Wang ES, Morrissette JJD, Eastburn DJ, et al. 2019; Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. Cancer Discov. 9:1050–63. DOI: 10.1158/2159-8290.CD-18-1453. PMID: 31088841.

5. Piloto O, Wright M, Brown P, Kim KT, Levis M, Small D. 2007; Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. Blood. 109:1643–52. DOI: 10.1182/blood-2006-05-023804. PMID: 17047150. PMCID: PMC1794049.

6. Kropp EM, Li Q. 2022; Mechanisms of resistance to targeted therapies for relapsed or refractory acute myeloid leukemia. Exp Hematol. 111:13–24. DOI: 10.1016/j.exphem.2022.04.001. PMID: 35417742.

7. Swerdlow SH, Campo E, editors. 2017. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. IARC;Lyon:

8. Alotaibi AS, Yilmaz M, Loghavi S, DiNardo C, Borthakur G, Kadia TM, et al. 2020; Emergence of BCR-ABL1 fusion in AML post-FLT3 inhibitor-based therapy: a potentially targetable mechanism of resistance - a case series. Front Oncol. 10:588876. DOI: 10.3389/fonc.2020.588876. PMID: 33194747. PMCID: PMC7606916.

9. Staudt D, Murray HC, McLachlan T, Alvaro F, Enjeti AK, Verrills NM, et al. 2018; Targeting oncogenic signaling in mutant FLT3 acute myeloid leukemia: the path to least resistance. Int J Mol Sci. 19:3198. DOI: 10.3390/ijms19103198. PMID: 30332834. PMCID: PMC6214138.